Iohexol and meglumine iothalamate in phlebography of the leg. Comparison of the tolerance.
Fifty patients were examined by ascending phlebography of both legs in a prospective, double blind, within-patient series. Each leg was randomly allocated to the examination using either iohexol 300 mg I/ml or meglumine iothalamate 280 mg I/ml as the contrast medium. Immediate side effects were recorded in all patients, and delayed effects in 45 patients. Statistical analysis using the chi-square test showed that iohexol produced significantly less immediate pain in the leg than meglumine iothalamate. Iohexol produced significantly less nausea, and vomiting during the injection than meglumine iothalamate. No significant difference was found in the incidence of delayed pain and swelling with either medium. The quality of the films produced by iohexol was significantly better than that obtained with meglumine iothalamate.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003287:Contrast Media / Q000633:toxicity*; D004311:Double-Blind Method; D004361:Drug Tolerance; D004487:Edema / Q000209:etiology; D005260:Female; D005483:Flushing / Q000209:etiology; D006801:Humans; D007463:Iodobenzoates / Q000633:toxicity*; D007472:Iohexol; D007482:Iothalamate Meglumine / Q000633:toxicity*; D007866:Leg / Q000098:blood supply / Q000000981:diagnostic imaging*; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000209:etiology; D010690:Phlebography; D011897:Random Allocation; D014283:Triiodobenzoic Acids / Q000633:toxicity*
D003287:Contrast Media; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D007472:Iohexol; D007482:Iothalamate Meglumine